« Back to Record
Citation APA

Leal, T., Kotecha, R., Ramlau, R., Milanowski, J., Cobo, M., Roubec, J., Petruzelka, L., Havel, L., Kalmadi, J., Ward, J., Andrić, Z., Berghmans, T., Gerber, D. E., Kloecker, G., Panikkar, R., Aerts, J. J., Delmonte, A., Pless, M., Greil, R., Rolfo, C., A Beccara, W., Eaton, M., Iqbal, M., & Langer, C. (2023). Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet oncology, 24, 1002-1017.


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/362469

Leal, T., Kotecha, R., Ramlau, R., Milanowski, J., Cobo, M., Roubec, J., Petruzelka, L., Havel, L., Kalmadi, J., Ward, J., Andrić, Z., Berghmans, T., Gerber, D. E., Kloecker, G., Panikkar, R., Aerts, J. J., Delmonte, A., Pless, M., Greil, R., Rolfo, C., A Beccara, W., Eaton, M., Iqbal, M., & Langer, C. (2023). Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study. Lancet oncology, 24, 1002-1017.